Numis Securities restated their buy rating on shares of Ergomed (LON:ERGO) in a research report report published on Thursday morning, Digital Look reports. They currently have a GBX 267 ($3.49) price target on the stock, up from their previous price target of GBX 190 ($2.48).
Shares of ERGO traded up GBX 1 ($0.01) during midday trading on Thursday, hitting GBX 234 ($3.06). The company had a trading volume of 86,000 shares, compared to its average volume of 28,490. The company has a market capitalization of $109.78 million and a P/E ratio of -11.70. Ergomed has a 52 week low of GBX 145 ($1.89) and a 52 week high of GBX 248 ($3.24). The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.48 and a current ratio of 1.48.
In related news, insider Jan Petracek bought 79,405 shares of the company’s stock in a transaction dated Tuesday, April 16th. The stock was bought at an average price of GBX 153 ($2.00) per share, with a total value of £121,489.65 ($158,747.75).
Ergomed plc provides clinical research, and drug development and safety and medical information services in the United Kingdom and internationally. The company offers clinical development, trial management, and pharmacovigilance services for pharmaceutical and generics companies, as well as small and mid-sized drug development companies.
Featured Story: Moving Average Convergence Divergence (MACD)
Receive News & Ratings for Ergomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ergomed and related companies with MarketBeat.com's FREE daily email newsletter.